EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

Kelong Han iD, Parul Patel, Scott McCallister, Alex R Rinehart, Yash Gandhi, William Spreen, Raphael J Landovitz, Sinead Delany-Moretlwe, Mark A Marzinke iD, Todd McKeon, Piotr Budnik, Jean van Wyk und 1 weitere

Antimicrobial Agents and Chemotherapy · 06.05.2024

DOI: 10.1128/aac.01475-23 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 06.05.2024. Verfasst von Kelong Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pyridones, HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, GlaxoSmithKline (GSK), ViiV Healthcare (ViiV Healthcare Limited).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting cabotegravir is approved for pre-exposure prophylaxis and combination HIV treatment, both initiated with optional short-term oral lead-in (OLI). We evaluated the impact of OLI on long-acting cabotegravir pharmacokinetics. Cabotegravir plasma concentrations were compared between HIV-positive participants initiating injections with ( n = 278) or without ( n = 110) OLI in phase III treatment study FLAIR and in HIV-negative participants using OLI ( n = 263) in pivotal pre-exposure prophylaxis studies HPTN 083 and HPTN 084. Cabotegravir pharmacokinetic profiles were simulated in three populations (assigned-male-at-birth, 50%-assigned-female-at-birth, and assigned-female-at-birth) under three scenarios: first injection given (A) 1 or (B) 3 days after final OLI dose (OLI-injection gap) or (C) without OLI. The PK objective was 80% of participants achieving 4× in vitro protein-adjusted 90% maximal inhibitory concentration (PA-IC 90 ) and 50% achieving 8× PA-IC 90 . Observed trough concentrations ( C τ ) were similar with and without OLI ( P > 0.3). With a 3-day OLI-injection gap, simulated pre-injection C τ remained above PK objective. Approximately 1–2 weeks after the first injection, simulated PK profiles became nearly identical among all scenarios. Without OLI, it was predicted that 80% of participants achieve 4× PA-IC 90 in 1.2, 1.8, and 2.8 days after the first injection in each population, respectively, and 50% achieve 8× PA-IC 90 in 1.4, 2.1, and 3.8 days, respectively. Observed long-acting cabotegravir exposure was similar with or without OLI, supporting optional OLI use. Cabotegravir exposure was predicted to remain above PK objective for OLI-injection gaps of ≤3 days and rapidly achieve PK objective after first injection without OLI. Findings are consistent between assigned-male-at-birth and assigned-female-at-birth populations. This study is registered with ClinicalTrials.gov as NCT02720094 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsHumansMaleFemaleAdultAdministration, OralMiddle AgedDiketopiperazines

Stichwörter der Autor:innen

HIVcabotegraviroral lead-inpharmacokineticspre-exposure prophylaxis

Substanzen

cabotegravirPyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • ViiV Healthcare, Durham, North Carolina, USA.
  • ViiV Healthcare, Branford, Connecticut, USA.
  • Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
  • Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Kelong Han, Mark A Marzinke

Förderung

  • NIAID NIH HHS
  • GlaxoSmithKline (GSK)
  • ViiV Healthcare (ViiV Healthcare Limited)

Zitieren

APA

Han, K., Patel, P., McCallister, S., Rinehart, A. R., Gandhi, Y., Spreen, W., Landovitz, R. J., Delany-Moretlwe, S., Marzinke, M. A., McKeon, T., Budnik, P., van Wyk, J., & Ford, S. L. (2024). Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01475-23

Vancouver

Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, et al. Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01475-23

BibTeX
@article{Han2024,
  author = {Han, Kelong and Patel, Parul and McCallister, Scott and Rinehart, Alex R and Gandhi, Yash and Spreen, William and Landovitz, Raphael J and Delany-Moretlwe, Sinead and Marzinke, Mark A and McKeon, Todd and Budnik, Piotr and van Wyk, Jean and Ford, Susan L},
  title = {Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01475-23}
}
Kostenlos starten →